{"id":801703,"date":"2026-08-03T20:34:09","date_gmt":"2026-08-03T20:34:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/801703\/"},"modified":"2026-08-03T20:34:09","modified_gmt":"2026-08-03T20:34:09","slug":"obsidian-completes-galera-merger-with-350m-private-placement-financing","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/801703\/","title":{"rendered":"Obsidian Completes Galera Merger with $350M Private Placement Financing"},"content":{"rendered":"<p class=\"has-background\" style=\"background-color:#bebebe\">Why This Matters: Check out Contract Pharma\u2019s <a href=\"https:\/\/www.contractpharma.com\/exclusives\/2024-pharmaceutical-industry-mergers-acquisitions-roundup\/\" rel=\"nofollow noopener\" target=\"_blank\">Pharmaceutical Industry Mergers &amp; Acquisitions Roundup<\/a>.<\/p>\n<p><a href=\"https:\/\/obsidiantx.com\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Obsidian Therapeutics<\/a> completed a previously announced transaction that brings Galera Therapeutics under the Obsidian name. Before closing the merger, Obsidian also completed an oversubscribed private placement financing of $350 million.<\/p>\n<p>As a clinical-stage biopharmaceutical company, Obsidian uses novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies. Among these: lead candidate OBX-115, in trials for non-small cell lung cancer (NSCLC, Phase I) and advanced melanoma (Phase II).<\/p>\n<p>In fact, the U.S. FDA granted OBX-115 Fast Track and Regenerative Medicine Advanced Therapy status in unresectable or metastatic melanoma.<\/p>\n<p>Obsidian Lends Tech to Galera Partnership<\/p>\n<p>Obsidian is leveraging its cytoDRIVE platform in order to develop engineered TIL cell therapies like OBX-115. The proprietary technology precisely regulates timing and level of protein function through the use of FDA-approved small-molecule drugs.<\/p>\n<p>OBX-115 has potential, Obsidian says, to reduce overall treatment burden. Additionally, options exist for minimally invasive core needle biopsy tumor tissue procurement, exclusively low-dose lymphodepletion compatible with outpatient administration.<\/p>\n<p>\u201cWe are well-positioned to deliver best-in-class TIL cell therapies to patients with solid tumors,\u201d Obsidian CEO Madan Jagasia, MD, said.<\/p>\n<p>Jagasia added enrollment of patients with immune checkpoint inhibitor-resistant advanced melanoma in the registration-enabling cohort of Obsidian\u2019s study is imminent.<\/p>\n<p>Data from the Phase I NSCLC trial are expected in the first half of 2027. Topline data from the melanoma trial should be coming by end of 2027.<\/p>\n<p>Merger Financial Details<\/p>\n<p>The oversubscribed private placement financing included both a syndicate of new investors, and multiple pre-existing investors in Obsidian.<\/p>\n<p>At closing, the financial balance of Obsidian and Galera combined funds operations into the second half of 2028. This timeline provides a runway for the expected key clinical milestones for OBX-115.<\/p>\n<p>Obsidian\u2019s offices are located in two sites in Massachusetts, in Cambridge and Bedford.<\/p>\n","protected":false},"excerpt":{"rendered":"Why This Matters: Check out Contract Pharma\u2019s Pharmaceutical Industry Mergers &amp; Acquisitions Roundup. Obsidian Therapeutics completed a previously&hellip;\n","protected":false},"author":2,"featured_media":801704,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[4,450,451,3,452,453],"class_list":["post-801703","post","type-post","status-publish","format-standard","has-post-thumbnail","category-breaking-news","tag-breaking-news","tag-breakingnews","tag-headlines","tag-news","tag-top-stories","tag-topstories"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/801703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=801703"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/801703\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/801704"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=801703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=801703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=801703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}